Year: 2026

Introduction The global pharmaceutical industry has fundamentally shifted toward outsourcing — and at the heart of this shift is the contract manufacturing pharmaceutical company, or CDMO (Contract Development and Manufacturing Organization). Rather than building and operating their own manufacturing infrastructure, pharmaceutical companies of all sizes are partnering with specialized contract manufacturers to produce APIs, formulations, biologics, and packaging at scale, speed, and lower cost. India has emerged as the world’s most strategic destination for pharmaceutical contract manufacturing. The India CDMO market was valued at USD 8.52 billion in 2025 and is projected to reach USD 16.53 billion by 2034, growing at a CAGR of 7.39%. Driven by India’s deep generics manufacturing heritage, world-class regulatory compliance, and cost-competitive infrastructure, Indian CDMOs now serve global pharmaceutical companies from startups to multinational innovators. This guide explains exactly what pharmaceutical contract manufacturing is, what services it covers, how to evaluate a CDMO partner, the top companies in India, and why Salvavidas Pharmaceutical Pvt. Ltd. is a trusted choice for businesses seeking a reliable manufacturing partner. What Is a Contract Manufacturing Pharmaceutical Company (CDMO)? A Contract Development and Manufacturing Organization (CDMO) — or Contract Manufacturing Organization (CMO) — is a company that provides pharmaceutical manufacturing services to other pharmaceutical companies on a contractual basis. Rather than the client building their own facility, the CDMO manufactures products on their behalf, using the client’s formula, or developing the formulation and manufacturing it end-to-end. Core Services Offered by a Pharmaceutical Contract Manufacturer: *API Manufacturing — Production of Active Pharmaceutical Ingredients (bulk drugs) *Finished Dosage Form (FDF) Manufacturing — Tablets, capsules, injectables, syrups, topicals *Formulation Development — Creating and optimizing drug formulations for stability and bioavailability Process Development — Scaling laboratory processes to commercial manufacturing *Packaging Services — Primary and secondary packaging, labeling, serialization *Analytical & Regulatory Support — Quality testing, stability studies, regulatory dossier preparation *Clinical Supply Manufacturing — Small-scale production for clinical trials India’s Pharmaceutical Contract Manufacturing Market: Key Numbers (2025–2026) Contract manufacturing services dominate India’s CDMO market with a 53.8% share in 2025, driven by strong demand for API production, finished dosage form manufacturing, and biologics outsourcing. Metric Data India CDMO Market Value (2025) USD 8.52 Billion – USD 25.51 Billion* Projected Market Value (2034–2035) USD 16.53 Billion – USD 71.14 Billion* CAGR (2026–2034) 7.39% – 10.80%* Contract Manufacturing Share 53.8% of total CDMO market Small Molecule Dominance 67.2% of India CDMO market Sterile Injectable CAGR (Global) 9.05% through 2031 Oncology Segment Share 32.15% of global CDMO revenue API Segment Share 51.78% – 54.92% of revenue Range reflects varying estimates across multiple market research sources. India’s CDMO market is driven by a large pool of skilled scientists, cost-effective manufacturing capabilities, and a well-established generic and biosimilars industry. It is expected to grow at a CAGR of 10.80% during 2026–2035 and attain a market value of USD 71.14 billion by 2035. Why India Is the World’s Most Preferred Pharmaceutical Contract Manufacturing Destination 1. Deep Generics Manufacturing Heritage India is the world’s largest producer of generic drugs, accounting for 20% of the worldwide supply by volume and supplying about 60% of the global vaccination demand — well-positioned to meet this demand through its robust CDMO infrastructure. 2. Significant Cost Advantage India’s ability to offer low-cost manufacturing without compromising on quality has positioned it as a preferred destination for pharmaceutical outsourcing. The country benefits from lower labor costs, reduced operational expenses, and economies of scale, making it highly competitive compared to Western countries. 3. Regulatory Alignment with Global Standards India holds more USFDA-approved manufacturing facilities outside the US than any other country. Indian CDMOs’ adherence to international regulatory standards, coupled with their ability to provide end-to-end solutions from research and development to manufacturing, attracts global pharmaceutical companies. 4. “China Plus One” Strategic Advantage The U.S. Congress passed the “BIOSECURE Act” restricting federal contracts with certain foreign biotech firms, prompting U.S. pharma companies to shift contracts from China to India — creating a massive tailwind for Indian CDMOs as “China Plus One” beneficiaries. 5. Government Policy Support India’s Production Linked Incentive (PLI) scheme, the Make in India initiative, and harmonized regulatory standards continue to attract both domestic and foreign investment into pharmaceutical contract manufacturing — reducing barriers and increasing global competitiveness. 6. Skilled Scientific Workforce Indian CDMOs benefit from a long history in generic drug manufacturing, which has shaped a workforce skilled in process optimization, scale-up, and regulatory compliance — now being applied to more advanced services including biologics, cell and gene therapies, and niche formulations. Types of Pharmaceutical Contract Manufacturing Services in India API Contract Manufacturing The largest segment of India’s CDMO market, covering synthesis and production of Active Pharmaceutical Ingredients for generic and branded drug manufacturers worldwide. Small molecules exhibit clear dominance with a 67.2% share of the total India CDMO market in 2025. Finished Dosage Form (FDF) Contract Manufacturing Production of ready-to-dispense pharmaceutical formulations: *Solid orals — Tablets, capsules, sachets *Liquid orals — Syrups, suspensions, dry syrups *Sterile injectables — Ampoules, vials, pre-filled syringes *Topicals — Creams, ointments, transdermal patches *Inhalers — MDIs, dry powder inhalers Biologics & Biosimilar Contract Manufacturing Large molecules/biologics are projected to grow at a 15.26% CAGR, challenging small-molecule dominance — with Indian CDMOs investing in mammalian cell culture, monoclonal antibody production, and single-use bioreactor systems. Third-Party / Private Label Manufacturing Businesses without their own manufacturing infrastructure outsource production under their own brand name. This model is widely used by: *PCD (Propaganda Cum Distribution) pharma franchise businesses *Regional and national pharmaceutical distributors *New pharma brands entering the market without capital-intensive facility investment *International importers and distributors in semi-regulated markets High-Potency API (HPAPI) Manufacturing HPAPIs are projected to grow at an 8.05% CAGR to 2031 — driven by the expansion of oncology drug pipelines requiring specialized containment manufacturing capabilities. How to Choose the Right Contract Manufacturing Pharmaceutical Company Selecting a CDMO partner is one of the most consequential supply-chain decisions a pharmaceutical company will make. Here is the evaluation framework experienced buyers use: 1. Regulatory Certifications Confirm the facility holds WHO-GMP as a

Introduction Among all pharmaceutical dosage forms, sterile injectables carry the highest manufacturing risk and the lowest tolerance for error. Because injectable products bypass the body’s natural defenses and are introduced directly into the bloodstream, muscle, or tissue, even microscopic contamination can cause serious harm. This is why sterile injectable manufacturing is governed by some of the most demanding regulatory and engineering standards in the entire pharmaceutical industry. India has emerged as a global hub for sterile injectable production — combining advanced aseptic processing infrastructure with cost-competitive manufacturing. But not every facility that produces injectables operates at true sterile manufacturing standards. For hospitals, distributors, and pharmaceutical companies sourcing parenteral products, understanding what genuine sterile manufacturing requires is essential to choosing the right partner. This guide goes deep into the technical foundation of sterile injectable manufacturing in India — aseptic processing, cleanroom classifications, fill-finish technology, sterility assurance — and explains why Salvavidas Pharmaceutical Pvt. Ltd. approaches sterile manufacturing with the rigor this category demands. What Makes a Product “Sterile”? A pharmaceutical product is classified as sterile when it is completely free from viable microorganisms. For injectable (parenteral) products, regulatory bodies set an extremely high bar: an injectable can only be classified as sterile once it achieves a probability of microbial contamination of less than one in one million units — known as the Sterility Assurance Level (SAL). Achieving this level of assurance is not a single step — it is the result of an entire manufacturing ecosystem engineered around contamination prevention, from raw material handling through final packaging. Why Sterile Injectable Manufacturing Is Different from Other Dosage Forms Drug products delivered via the parenteral, ophthalmic, inhaled, or otic route present an increased risk of infection or harm because they bypass many of the body’s natural defenses. This is precisely why regulatory authorities mandate that such products be supplied only as sterile preparations. Unlike tablets or capsules — which can often be terminally sterilized after final packaging — many modern injectable products (biologics, monoclonal antibodies, certain proteins and enzymes) are heat-sensitive or otherwise cannot withstand terminal sterilization. These products must instead be manufactured using aseptic processing, where every component — the drug substance, the container, and the closure — is sterilized separately and then combined in a controlled environment that prevents any contamination from entering the final product. This requirement is what makes injectable manufacturing facilities the most sophisticated and challenging pharmaceutical facilities to design, build, and operate. Understanding Cleanroom Classifications in Sterile Manufacturing Aseptic processing and sterile fill-finish operations take place in cleanrooms specifically designed to control the flow of personnel, materials, and equipment to minimize contamination risk. Cleanrooms are organized in a cascading design, where air quality increases progressively as you move closer to the most critical zone of the facility. Grade / ISO Class Description Use in Sterile Manufacturing Grade A / ISO 5 Critical zone — highest air quality, Class 100 Aseptic filling, stopper/vial handling, open product exposure Grade B / ISO 7 Background environment for Grade A zone Surrounding area for the aseptic core Grade C / ISO 8 Controlled processing areas Preparation of solutions, less critical processing Grade D Supporting/gowning areas Personnel gowning, material staging, non-sterile prep The flow of personnel, materials, and equipment typically begins in supporting, lower-grade areas — where gowning and non-sterile preparation occur — and proceeds inward toward the Grade A critical zone, where the actual aseptic filling takes place. The Sterile Fill-Finish Process Sterile fill-finish is the final and most critical step in injectable manufacturing — where the drug product is filled into its final containers (vials, ampoules, pre-filled syringes, or cartridges) under strictly controlled aseptic conditions. Key stages include: 1. Component Sterilization Because the active ingredient remains in powder form until reconstitution, dry syrups avoid the degradation that occurs when moisture-sensitive drugs are stored in liquid form for long periods — making them ideal for distribution across long supply chains and varied climates. Strong Market Growth The global dry syrup market — which includes pediatric pharmaceuticals and antibiotic treatments — is expected to grow at a steady CAGR through 2028, driven by the increased occurrence of respiratory infections and other treatable conditions in children. India’s broader cold and cough remedies market alone is projected to reach significant value by 2025–2026, reflecting strong sustained demand. Widespread OTC and Prescription Use Dry syrups span both prescription antibiotic therapy and over-the-counter (OTC) categories like multivitamins and cough remedies, giving manufacturers a broad and resilient market. Why India Leads in Dry Syrup Manufacturing 1. Cost-Effective Production Vials, stoppers, and other container components are sterilized independently — often via dry heat depyrogenation or autoclaving — before entering the aseptic core. 2. Sterile Filtration The drug solution is passed through sterilizing-grade filters (typically 0.22 micron) within an ISO 5 environment, using closed, single-use filtration systems to minimize human contact with the product. 3. Aseptic Filling The sterile solution is filled into pre-sterilized containers under Grade A conditions. Modern facilities increasingly use isolator technology and Restricted Access Barrier Systems (RABS) to physically separate operators from the critical processing zone — significantly reducing the single greatest source of contamination risk: human presence. 4. Stoppering & Capping Containers are sealed immediately after filling, still within the controlled aseptic environment, to prevent any post-fill contamination. 5. Lyophilization (Where Applicable) For freeze-dried (lyophilized) injectables, partially stoppered vials are transferred to sterile freeze-dryers, where the product is dried under vacuum before full stoppering — all within the aseptic boundary. 6. Environmental Monitoring Continuous monitoring of particulate counts, microbial levels, temperature, humidity, and pressure differentials throughout the process ensures the cleanroom maintains its required classification at all times. Aseptic Processing Technologies Used in Modern Sterile Facilities This is the foundational quality benchmark. Always confirm current certification status directly with the manufacturer. Technology Function Isolator Systems Physically isolates the aseptic core from operators using glove-port access, drastically reducing contamination risk RABS (Restricted Access Barrier Systems) Provides a barrier between operators and the critical zone while allowing more flexible access than full isolators Vapor-Phase Hydrogen

Introduction Dry syrups are among the most widely prescribed pharmaceutical formulations in India and across the developing world — particularly for pediatric patients and antibiotic therapy. Their extended shelf stability, ease of dosing, and broad acceptance among doctors and patients have made them a cornerstone product category for pharmaceutical manufacturers. India has become a global hub for dry syrup manufacturing, combining affordable production with increasingly rigorous quality standards. Today, there are a number of WHO-GMP-certified dry syrup manufacturers in India, supplying not just the domestic market but exporting to more than 50 countries. This guide explains what dry syrups are, why India leads in their manufacturing, what to look for in a reliable manufacturer, the top companies in this space, and why Salvavidas Pharmaceutical Pvt. Ltd. is a trusted partner for quality-driven pharmaceutical manufacturing. What Is a Dry Syrup? A dry syrup is a powdered pharmaceutical formulation that is reconstituted with water before use, rather than being supplied as a ready-to-use liquid. This format is used specifically for drugs that are chemically unstable in liquid (aqueous) form over extended periods — most commonly antibiotics like Amoxicillin, Cefixime, and Azithromycin. Key characteristics of dry syrups: *Supplied as a powder or granules in a bottle *Reconstituted with water by the pharmacist or caregiver at the time of dispensing *Offers significantly longer shelf life than pre-mixed liquid formulations *Once reconstituted, typically has a shorter usable window (7–14 days, refrigerated) *Commonly used for pediatric antibiotics, multivitamins, and other moisture-sensitive drugs Dry syrups are the medicine of choice for many pediatric treatments since they are safe, easy to administer, and allow flexible dosing based on a child’s body weight. Why Dry Syrups Are in High Demand The injectable manufacturing sector in India is rapidly expanding due to rising chronic diseases, hospital expansions, increased exports, and the thriving contract/third-party pharma manufacturing model — making it one of the most profitable and fast-growing segments of the pharmaceutical industry. Pediatric-Friendly Dosing Dry syrups allow precise, weight-based dosing for children — a critical requirement in pediatric medicine where tablet formulations are often impractical. Extended Shelf Stability Because the active ingredient remains in powder form until reconstitution, dry syrups avoid the degradation that occurs when moisture-sensitive drugs are stored in liquid form for long periods — making them ideal for distribution across long supply chains and varied climates. Strong Market Growth The global dry syrup market — which includes pediatric pharmaceuticals and antibiotic treatments — is expected to grow at a steady CAGR through 2028, driven by the increased occurrence of respiratory infections and other treatable conditions in children. India’s broader cold and cough remedies market alone is projected to reach significant value by 2025–2026, reflecting strong sustained demand. Widespread OTC and Prescription Use Dry syrups span both prescription antibiotic therapy and over-the-counter (OTC) categories like multivitamins and cough remedies, giving manufacturers a broad and resilient market. Why India Leads in Dry Syrup Manufacturing 1. Cost-Effective Production India’s manufacturing infrastructure, skilled labor, and efficient raw material sourcing allow dry syrup manufacturers to offer high-quality products at significantly lower costs than Western counterparts. 2. Strong Regulatory Framework Reputable Indian dry syrup manufacturers operate under WHO-GMP and ISO certification, with regular oversight from drug regulatory authorities — ensuring consistent quality and safety standards. 3. Export-Ready Infrastructure Indian dry syrup manufacturers are not limited to domestic supply — many export to 50+ countries, supported by established documentation and logistics processes for international shipment. 4. Low Barrier to Entry for New Businesses Because many manufacturers offer third-party and contract manufacturing services, new pharma businesses and entrepreneurs can launch dry syrup product lines without investing in their own manufacturing plant — a major driver of industry growth in India. 5. R&D-Driven Formulation Improvements Leading manufacturers invest in R&D specifically to improve shelf life, taste masking (important for pediatric compliance), and achieve precise, consistent dosing. What to Look for in a Dry Syrup Manufacturer in India WHO-GMP & ISO Certification This is the foundational quality benchmark. Always confirm current certification status directly with the manufacturer. Formulation & R&D Capability A manufacturer with an active R&D team can support taste-masking, stability optimization, and customized formulations — particularly important for pediatric products where palatability affects compliance. Quality Control Systems Look for manufacturers with dedicated QA staff conducting in-process inspection, batch testing, and water-quality testing (water is a critical raw material in reconstitution-based products). Packaging Options Reliable manufacturers offer a range of bottle sizes and materials (HDPE, Amber PET) with tamper-evident caps — important for both safety and shelf appeal. Production Capacity & Scalability Confirm the manufacturer’s daily production capacity and ability to scale with your order growth without compromising quality or delivery timelines. Regulatory & Documentation Support For startups and smaller pharma businesses, manufacturers that provide drug licenses, batch manufacturing records, and regulatory assistance significantly reduce the operational burden of launching a product. Third-Party / Private Label Manufacturing If you are a distributor, PCD franchise business, or new pharma brand, confirm whether the manufacturer supports private labeling and custom branding. Top Dry Syrup Manufacturers in India (2025–2026) 1. Salvavidas Pharmaceutical Pvt. Ltd. — Surat, Gujarat ⭐ Recommended Salvavidas Pharmaceutical Pvt. Ltd. brings the discipline of WHO-GMP certified manufacturing to its pharmaceutical formulations, including dry syrups, with a strong focus on quality control and consistent product performance. Headquartered in Surat, Gujarat — a major pharmaceutical manufacturing hub — Salvavidas serves both domestic and international buyers with reliable, well-documented products. Salvavidas at a Glance: Feature Details Certification WHO-GMP Certified Product Range Dry Syrups, Formulations, APIs, Intermediates Therapeutic Areas Anti-infective, Pediatric, Cardiovascular, Neurology & more Markets Served Asia, Africa, Europe, Middle East Documentation CoA, COPP, Free Sale Certificate, GMP Certificate Approach Quality-first manufacturing, transparent communication For pharma businesses, distributors, and importers seeking a manufacturing partner that combines regulatory rigor with responsive service, Salvavidas Pharmaceutical offers a dependable foundation for dry syrup sourcing. 🧴 Looking for a trusted dry syrup manufacturer in India? Contact Salvavidas Pharmaceutical Pvt. Ltd. for product details, certifications, and documentation support. 📧 info@salvavidas.com 2. Sun Pharmaceutical Industries